Preventing Relapse of Major Depression During Interferon-α Therapy for Hepatitis C—A Pilot Study - Digestive Diseases and Sciences

1. Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Calès P, Garré JB (2003) Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry 4:115–118

   Article  PubMed  Google Scholar 

2. El-Serag HB, Kunik M, Richardson P, Rabeneck L (2002) Psychiatic disorders among veterans with hepatitis C infection. Gastroenterology 123:476–482

   Article  PubMed  Google Scholar 

3. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C, ANRS HCO2 RIBAVIC Study Team (2004) Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292(23):2839–2848

   Article  PubMed  CAS  Google Scholar 

4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347(13):975–982

   Article  PubMed  CAS  Google Scholar 

5. Complete Product Information and Pegasys Medication Guide (2006) Available at: http:/www.rocheusa.com/products/pegasys/ pi.pdf; retrieved July 12, 2006

6. Peg Intron (2006) Product Information Page. Rev. 02/05. Available at: http://www.spfiles.com/pipeg-intron.pdf; retrieved August 17, 2006

7. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD (2002) A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 7:942–947

   Article  PubMed  CAS  Google Scholar 

8. Gleason OC, Yates WR (1999) Five cases of interferon-alfa-induced depression treated with antidepressant therapy. Psychosomatics 40:510–512

   PubMed  CAS  Google Scholar 

9. Levenson JL, Fallon HJ (1993) Fluoxetine treatment of depression caused by interferon-alfa. Am J Gastroenterol 88:760–761

   PubMed  CAS  Google Scholar 

10. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG (2000) Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 173:359–361

    PubMed  CAS  Google Scholar 

11. Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M (2002) Paroxetine for the treatment of interferon-alfa-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 16:1091–1099

    Article  PubMed  CAS  Google Scholar 

12. Goldman LS (1994) Successful treatment of interferon alfa-induced mood disorder with nortiptyline [letter]. Psychosomatics 35:412–413

    PubMed  CAS  Google Scholar 

13. Gleason OC, Yates WR, Isbell MD, Philipsen MA (2002) An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 36:194–198

    Google Scholar 

14. Gleason OC, Yates WR, Philipsen MA (2005) Major depressive disorder in hepatitis C: an open-label trial of escitalopram. Prim Care Compan J Clin Psychiatry 7(5):225–230

    Google Scholar 

15. Loftis JM, Hauser P (2003) Safety of the treatment of interferon-alpha-induced depression [letter]. Psychosomatics 44:524–526

    Article  PubMed  Google Scholar 

16. Hejny C, Sternburg P, Lawson DH, Greiner K, Aaberg Jr TM (2001) Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Opthalmol 131:782–787

    Article  CAS  Google Scholar 

17. Ozcanli T, Unsalver B, Ozdemir S, Ozmen M (2005) Sertraline- and mirtazapine-induced severe neutropenia [letter]. Am J Psychiatry 162:1386

    Article  PubMed  Google Scholar 

18. Choi S (2003) Nefazadone (Serzone) withdrawn because of hepatotoxicity. CMAJ 169:1187

    PubMed  Google Scholar 

19. Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, Heinz A, van Boemmel F, Berg T (2005) Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 42(6):793–798

    Article  PubMed  CAS  Google Scholar 

20. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM (2000) Hepatitis C, interferon alfa, and depression. Hepatology 31:1207–1211

    Article  PubMed  CAS  Google Scholar 

21. Sheehan DV, Lecrubier Y, Harnett-Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview. J. Clin Psychiatry 59(Suppl 20):22–33

    PubMed  Google Scholar 

22. Hamilton M (1976) Hamilton Depression Scale. In: ECDEU assessment manual for psychopharmacology. Rev. ed. Guy W (ed). U.S. Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, pp 179–192

23. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198

    Article  PubMed  CAS  Google Scholar 

24. Berg R, Franzen M, Wedding D (1987) Screening for brain impairment: a manual for mental health practice. Springer, New York

    Google Scholar 

25. Derogatis LR (2000) Symptom Checklist-90-Revised (SCL-90-R) In: Task force for the handbook of psychiatric measures. Handbook of psychiatric measures. American Psychiatric Association, Washington, DC, pp 81–84

    Google Scholar 

26. Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). 1. Conceptual framework and item selection. Med Care 30:473–483

    Article  PubMed  Google Scholar 

27. National Institute of Mental Health (1970) CGI: clinical global impressions. In: Manual for the ECDEU assessment battery, 2. Rev ed. Guy W, Bonato RR (eds). Chevy Chase, MD: National Institute of Mental Health, pp 12-1–12-6

Download references